Saturday, Merck & Co Inc (NYSE:MRK) announced results from the Phase 3 KEYNOTE-564 trial evaluating Keytruda for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
At the third pre-specified interim analysis (median follow-up of 57.2 months, Keytruda as adjuvant therapy (after surgery) significantly improved overall survival (OS), the trial’s key secondary endpoint, by 38% compared to placebo.
At 48 months, ...